🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just out in JAMA Network Open 🚨 University of Iowa Urology Vignesh Packiam, MD show Gem/doce associated w/ nearly 50% reduction in recurrences and lower rate of tx discontinuation compared to bcg for high risk #nmibc 👏 Society of Urologic Oncology Bladder Cancer Advocacy Network UroToday.com Link: tinyurl.com/m6yf3nc3

Gem+Doce is associated with better 2yr high-grade recurrence-free survival (81% vs 69%), less treatment discontinuation (3% vs 9%) vs BCG in patients with non–muscle-invasive bladder cancer; may be useful during BCG shortage. Vignesh Packiam, MD Ian McElree ja.ma/3IGhX1U

Very proud to be a part of bringing Gem/Doce to light! Thanks to everyone involved.

Further evidence that Gem/Doce is reasonable alternative to BCG in patients with high-risk NMIBC, during the ongoing BCG shortage Ian McElree Vignesh Packiam, MD Ryan L. Steinberg MD University of Iowa ja.ma/41ToYFt JAMA Network Open JAMA Network #Bridge Trial Max Kates Angie Smith

Change is good!

What an honor - Thanks Journal of Urology for recognizing our work 🫡 Still much to be done! Vignesh Packiam, MD Ryan L. Steinberg MD

Someday soon enough bcg is not going to be the standard of care #nmibc … alternative therapies are coming . In the meantime I’ll keep sending my napkin results to Vignesh Packiam, MD and our 🐁 results .. 40% CR Gem Doce / 40 % CR alternative 🦠 .. bcg 👎🏻 #bladdercancer

Really impactful science Laura Bukavina - you are awesome work with! Gem/Doce 📈📈📈 this is great for our patients Important translational work in the works Ian McElree Max Kates Eugene Pietzak Saum Ghodoussipour Bladder Cancer Advocacy Network

Pooling together patients from MD Anderson Cancer Center Moffitt Cancer Center University of Iowa we report outcomes of IR-NMIBC patients treated with Gem-Doce vs BCG in European Urology Oncology Ian McElree Facundo Davaro Ryan L. Steinberg MD Kelly Bree Neema Navai #ColinDinney #MikeODonnell Roger Li Ashish M. Kamat, MD, MBBS Vignesh Packiam, MD

Continued great work by super 🌟 Ian McElree Gem/Doce effective in treatment naive (79% 2 year RFS) and previously treated (64%) Intermediate Risk NMIBC Ryan L. Steinberg MD Joanna Orzel, M.D. Bladder Cancer Advocacy Network YUO Can be considered for various disease states pubmed.ncbi.nlm.nih.gov/37442741/

💥New 📝 Alert💥 Gem/Doce for HG Favorable UTUC 📍41 UT units, 90% CIS (+cytology) 📍2yr RFS 54%, 3yr PFS 75% 📍2 yr NephU Free 92% 🛑 5 pts died of UTUC Reasonable option 4 selected patients! tinyurl.com/GemDoceUTUC University of Iowa Urology Vignesh Packiam, MD Ian McElree #MikeODonnell

Such a privilege to continue working with Ian McElree on use of endoluminal Gem/Doce, now for #UTUC Takeaways: 🟡 41 upper tracts - 90% CIS (most had + cytology) 🟡 2 yr-RFS 54%, 2yr-NephUFS 92% 🟡 👤 selection is 🔑 #GemDoce #SaveTheNephrons Vignesh Packiam, MD University of Iowa Urology

Ecstatic and humbled to be joining Mayo Clinic Urology for residency! What a dream come true. Rochester, here we come! 🎉🎉🎉 #auamatch #uromatch #urosome #IowaMatch2024

Fantastic work by Ian McElree (as always!) presenting on BCG vs Gem/Doce in upper tract CIS. Similar outcomes with regards to RFS/NFS/OS. But be careful of the potential for infection! #AUA24 #SaveTheNephrons #GemDoce #UTUC Vignesh Packiam, MD University of Iowa Urology

Nice paper Reuben Ben-David ד''ר ראובן בן דוד Dr. John Sfakianos !! Important to learn optimal Gem/Doce protocol. Data like this on the implications of maintenance are valuable. Anecdotally I have found that 2g Gem in combo regimens has more tol issues Saum Ghodoussipour Rutgers Cancer Institute Rutgers RWJ Urology Ian McElree

Another intravesicular regimen (cabazitaxel+ Gem) by Mike O'Donnell UI Holden Comprehensive Cancer Center with pembro, in refractory HRNMIBC (Doce failure), interesting results, prospective study underway. Honored to be part of this effort. mdpi.com/2873358 #mdpicancers via Cancers MDPI

Fantastic work by super ⭐️ Ian McElree presenting University of Iowa Urology data on restaging procedures for NMIBC. An important step when considering multiple salvage intravesical therapies. Keep an eye out for him in this year’s match! #NCSAUA24 North Central Section AUA Vignesh Packiam, MD

We are thrilled to share our recent publication in European Urology Oncology demonstrating for the first time CHAI based predictive biomarker to guide use of intravesical BCG vs alternatives (chemotherapy). In an era of BCG shortage and new alternatives to BCG incoming, precision medicine

New in European Urology Oncology, including University of Iowa Urology authors Dr. Michael A. O'Donnell, Dr. Jordan R. Richards, and Ian McElree: Investigation of first AI-powered histologic biomarker for patients with untreated high-grade NMIBC: buff.ly/bijSZKE

More great work by Ian McElree on the importance of bluelight & checking sanctuary sites in post induction HR NMIBC. Esp 🔑 when considering multiple rounds of salvage therapy! Helen Y. Hougen MD Vignesh Packiam, MD #MikeODonnell University of Iowa Urology journals.sagepub.com/doi/10.1177/23…